VistaGen Therapeutics, Inc. - FORM 10-Q - EX-32 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE AND FINANCIAL OFFICERS REQUIRED BY RULE 13A-14(B) AND SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - February 16, 2016

Attached files

file filename
EX-10.2 - FORM OF WARRANT EXCHANGE AGREEMENT - VistaGen Therapeutics, Inc.ex10-2.htm
EX-31.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER REQUIRED BY RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - VistaGen Therapeutics, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER REQUIRED BY RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - VistaGen Therapeutics, Inc.ex31-1.htm
10-Q - FORM 10-Q - VistaGen Therapeutics, Inc.vsta10q_dec312015.htm
Exhibit 32
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of VistaGen Therapeutics, Inc. (the “Company”) for the quarter ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Shawn K. Singh, JD, the Company’s Principal Executive Officer, and Jerrold D. Dotson, the Company’s Principal Financial Officer, certify, pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:

 
1.
The Report fully complies with the requirement of Section 13(a) or Section 15 (d) of the Securities Exchange Act of 1934, and

 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


February 16, 2016


/s/ Shawn K. Singh
Shawn K. Singh
Principal Executive Officer


/s/ Jerrold D. Dotson
Jerrold D. Dotson
Principal Financial Officer
 


 

 



 
 
 

VistaGen Therapeutics, Inc. Reports